Sterling Capital Management’s Royalty Pharma RPRX Stock Holding History

Sterling Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.7M	Buy	66,034 +46,519	+238%	+$2.42M	0.06%	238
2026 Q1	$936K	Sell	19,515 -13,876	-42%	-$608K	0.02%	530
2025 Q4	$1.29M	Sell	33,391 -3,554	-10%	-$136K	0.02%	558
2025 Q3	$1.3M	Sell	36,945 -2,396	-6%	-$86.7K	0.02%	551
2025 Q2	$1.42M	Sell	39,341 -21,325	-35%	-$707K	0.02%	510
2025 Q1	$1.89M	Buy	60,666 +26,071	+75%	+$826K	0.03%	376
2024 Q4	$883K	Buy	34,595 +8,071	+30%	+$214K	0.01%	672
2024 Q3	$750K	Buy	+26,524	New	+$735K	0.01%	682

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sterling Capital Management's RPRX Position: Q2 2026 in Review

Sterling Capital Management increased its Royalty Pharma (RPRX) stake by 238% in Q2 2026, buying an estimated $2.42M and bringing the position to 66,034 shares worth $3.7M. The position accounts for 0.06% of the portfolio, ranked #238.

Sterling Capital Management first reported a position in RPRX in Q3 2024 and has held it in 8 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Sterling Capital Management held 66,034 shares of Royalty Pharma worth $3.7M as of Q2 2026.
Sterling Capital Management bought 46,519 Royalty Pharma shares in Q2 2026, an estimated $2.42M.
Royalty Pharma made up 0.06% of Sterling Capital Management's portfolio in Q2 2026, its #238 holding.
Sterling Capital Management first reported a position in Royalty Pharma in Q3 2024 and has held it in 8 quarters since.
645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.